Dell Technologies Partners with Child Mind Institute to Test Synthetic Patients in Brain Health Research

How Synthetic Patients Are Generated Using Dell’s Computing Infrastructure

On July 30, 2026, Dell Technologies announced a collaboration with the Child Mind Institute to evaluate synthetic patient data as a tool for overcoming limitations in brain health studies. The initiative, led by Dr. Gregory Kiar’s research team, aims to address the persistent challenge of small sample sizes in neuroscience by generating artificial but realistic patient profiles. These synthetic datasets are designed to mirror real-world neurological and behavioral patterns without compromising patient privacy. The project focuses on improving the scalability and reliability of brain health research, particularly in pediatric populations where data collection is often difficult. By using advanced modeling techniques, the team hopes to create a scalable framework that can be shared across institutions to accelerate discoveries in mental health and cognitive development.

Health news

APOE Genotype Influences How Well Blood Tau Protein Predicts Cognitive DeclinePancreatic Cancer Hijacks Blood-Clotting System to Evade Immune AttackSurvey Reveals Most Men Unaware Dairy May Increase Prostate Cancer RiskTherapeutic Gardening Shows Promise for Mental Health in Adults with Chronic Illnesses

The synthetic patient models are built using Dell Technologies’ high-performance computing systems and AI-driven data synthesis tools. Researchers input anonymized, aggregated data from existing clinical studies to train generative models that produce realistic patient profiles. These profiles include variables such as age, genetic markers, cognitive test scores, and environmental factors relevant to brain health. The process ensures that the synthetic data retains statistical properties of real datasets while eliminating any risk of re-identification. Dr. Kiar emphasized that the goal is not to replace real patient data but to augment it, especially in cases where collecting sufficient samples is ethically or logistically challenging. Early tests show that models trained on synthetic data produce results comparable to those from limited real-world samples, suggesting potential for broader application in under-studied conditions.

Can Artificial Data Improve Equity in Brain Health Research?

One of the key motivations behind the project is to reduce disparities in neuroscience research by enabling more inclusive analysis. Synthetic data can be tailored to represent underrepresented groups, such as children from diverse socioeconomic or racial backgrounds, who are often missing from traditional studies. This approach allows researchers to test hypotheses across broader demographics without requiring proportional increases in real-world recruitment. Dell Technologies provided both hardware and technical expertise to optimize the data generation pipeline, ensuring compatibility with existing research workflows. The Child Mind Institute plans to validate the synthetic models against longitudinal studies to assess their predictive accuracy. If successful, the method could become a standard supplement in federated research networks where data sharing is restricted by privacy laws.

What is a synthetic patient in this context? A synthetic patient is an artificially generated profile that mimics real patient data in terms of statistical and behavioral characteristics, created using AI models trained on anonymized datasets to support research without exposing personal information.

Frequently Asked Questions

How does this approach help with sample size limitations? By generating additional data points that reflect real-world patterns, synthetic patients allow researchers to run more robust statistical analyses and machine learning models even when actual participant numbers are low, increasing the power of studies without new data collection.

Is synthetic data as reliable as real patient data for scientific conclusions? While synthetic data does not replace real patient data, early validation shows it can produce comparable results in preliminary analyses, particularly for hypothesis testing and model training, though final clinical insights still require confirmation with real-world data.